NEW YORK (GenomeWeb News) – Complete Genomics reported after the close of the market Monday that its first-quarter revenues declined 43 percent year over year, falling short of Wall Street's consensus estimate on the top line.

The Mountain View, Calif.-based whole human genome services firm had total revenues of $3.9 million for the three months ended March 31, compared to $6.8 million for the first quarter of 2011. Analysts, on average, expected sales of $4.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.